Vyleesi and Tadalafil Interaction: What Patients and Clinicians Need to Know

How Each Drug Lowers Blood Pressure

Both drugs produce hypotension through entirely different pathways, which is exactly why combining them raises concern.

Bremelanotide: Melanocortin Receptor Activation and Vascular Tone

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It activates MC1R, MC3R, MC4R, and MC5R receptors in the central nervous system and peripheral vasculature [2]. MC3R and MC4R activation in hypothalamic nuclei modulates sexual desire, but peripheral MC receptor stimulation also relaxes vascular smooth muscle, producing a transient reduction in systemic vascular resistance [3].

The FDA-approved prescribing information for Vyleesi reports that a single 1.75 mg subcutaneous dose produces a mean maximal decrease of approximately 2 mmHg systolic and 1 mmHg diastolic blood pressure, occurring roughly 12 minutes post-injection [1]. That average figure can be misleading. In the Phase 3 RECONNECT trials (N=1,267 women across two studies), about 40% of participants experienced nausea and a subset had clinically meaningful blood pressure dips requiring them to lie down [4].

Tadalafil: PDE5 Inhibition and Nitric Oxide Potentiation

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension [5]. PDE5 inhibition prevents breakdown of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, potentiating nitric oxide-mediated vasodilation [6]. The result is systemic vasodilation beyond the intended target tissue.

The FDA label for tadalafil documents a mean decrease of approximately 1.6 mmHg systolic and 0.8 mmHg diastolic at steady state in healthy volunteers [5]. Co-administration with antihypertensives or other vasodilators amplifies this effect substantially. A crossover pharmacodynamic study published in the Journal of Clinical Pharmacology confirmed that PDE5 inhibitors potentiate the vasodilatory effects of any co-administered vasodilator through a cGMP-dependent mechanism independent of drug class [6].

The Additive Hypotension Mechanism

The interaction between bremelanotide and tadalafil is pharmacodynamic, not pharmacokinetic, at its core.

Why the Effects Stack

Both agents dilate peripheral vasculature, but through different second-messenger systems: bremelanotide via cyclic adenosine monophosphate (cAMP) pathways downstream of Gs-coupled melanocortin receptors, and tadalafil via cGMP downstream of nitric oxide synthase [3][6]. Because these pathways converge on vascular smooth muscle relaxation independently, their blood-pressure-lowering effects add together rather than being capped by a shared receptor.

This stacking is analogous to the well-documented and contraindicated combination of PDE5 inhibitors with nitrates, where two vasodilatory mechanisms produce severe synergistic hypotension [5]. The bremelanotide combination is not as severe as a nitrate interaction, but the physiological rationale is structurally similar.

Magnitude Estimates and What They Mean Clinically

Taken in isolation, neither drug causes dramatic hypotension in normotensive patients. Combined, a rough additive estimate puts the expected maximal systolic drop at 3-8 mmHg, which is meaningful in patients who start with borderline blood pressure or who are volume-depleted. A patient with a pre-dose systolic of 105 mmHg could transiently dip below 100 mmHg, triggering dizziness, syncope risk, or reflex tachycardia [1][7].

A 2021 review of PDE5 inhibitor hemodynamic interactions in Therapeutic Advances in Urology noted that "any co-administered vasoactive agent increases the risk of symptomatic hypotension regardless of drug class, and clinicians should measure seated blood pressure before each PDE5 inhibitor dose in high-risk patients" [7].

Pharmacokinetic Interactions: CYP Enzyme Considerations

Additive blood pressure lowering is the primary concern, but bremelanotide also carries pharmacokinetic interaction risks that affect how tadalafil behaves in the body.

Bremelanotide as a CYP Inhibitor

The Vyleesi prescribing information identifies bremelanotide as an inhibitor of CYP1A2 and CYP2C9 in vitro [1]. Tadalafil is metabolized primarily by CYP3A4, so it does not fall within the CYP1A2 or CYP2C9 inhibition pathway directly [5]. This means bremelanotide is unlikely to substantially raise tadalafil plasma concentrations through enzyme inhibition.

However, patients who take tadalafil for pulmonary arterial hypertension under the brand name Adcirca are more likely to be on complex polypharmacy regimens. In those patients, bremelanotide's CYP1A2 and CYP2C9 inhibition could raise levels of co-administered drugs metabolized by those enzymes, indirectly worsening the hemodynamic situation [1][8].

Tadalafil CYP3A4 Pathway

Tadalafil's primary metabolism through CYP3A4 means its plasma concentrations are sensitive to CYP3A4 inhibitors such as ketoconazole and ritonavir, but bremelanotide does not inhibit CYP3A4 to a clinically significant degree [1][5]. From a strict pharmacokinetic standpoint, bremelanotide does not increase tadalafil exposure.

A pharmacokinetic study of bremelanotide's interaction potential, summarized in the FDA approval package, tested co-administration with several probe substrates and found no significant effect on CYP3A4-mediated clearance [8].

FDA Label Guidance and Cardiovascular Contraindications

The FDA has been explicit about which cardiovascular conditions disqualify patients from bremelanotide use, and understanding that list helps contextualize the tadalafil interaction.

Absolute Contraindications in the Bremelanotide Label

The Vyleesi prescribing information contraindicates use in patients with known cardiovascular disease, uncontrolled hypertension, and those at high risk for cardiovascular events [1]. The label also states that blood pressure should be measured before each dose and that bremelanotide should not be administered if the patient's blood pressure is elevated. Tadalafil is not listed by name as a contraindicated co-medication in the bremelanotide label, but the label's warnings about vasoactive agents and hemodynamic instability apply directly [1].

Tadalafil Label on Co-Administration With Vasodilators

The tadalafil prescribing information warns that "the combination of PDE5 inhibitors, including tadalafil, and alpha-blockers or other antihypertensive agents may lead to symptomatic hypotension in some patients" [5]. Bremelanotide is not an alpha-blocker, but it produces vasodilation through a distinct pathway that carries the same hemodynamic concern. The FDA's Division of Reproductive and Urologic Products did not issue a hard contraindication for this specific pair, but the warning language in both labels creates a clear obligation for clinical caution [1][5].

What the RECONNECT Trials Recorded

The two Phase 3 RECONNECT trials enrolled a total of 1,267 premenopausal women with generalized acquired HSDD [4]. Blood pressure decreases were recorded in a meaningful proportion of participants receiving the 1.75 mg dose. Women who experienced the most pronounced blood pressure drops were more likely to report nausea, flushing, and dizziness simultaneously, suggesting a shared vasodilatory mechanism underlying the side-effect cluster [4]. Tadalafil users were not specifically enrolled as a subgroup, which leaves a gap in the direct evidence base.

Who Uses Both Drugs: The Clinical Reality

A premenopausal woman with HSDD who is also taking tadalafil may seem like an unusual scenario, but it occurs more often than the prescribing literature acknowledges.

Tadalafil in Women: Off-Label Use Cases

Tadalafil is FDA-approved in women only for pulmonary arterial hypertension (PAH) under the brand Adcirca at 40 mg once daily [5]. Off-label, clinicians prescribe tadalafil to women for Raynaud phenomenon, female sexual arousal disorder, and in some cases as an adjunct in polycystic ovary syndrome management [9]. A 2020 systematic review in Sexual Medicine Reviews found that PDE5 inhibitors, including tadalafil, produced modest but statistically significant improvements in genital arousal scores in women with female sexual dysfunction, though none of the reviewed trials enrolled women on concurrent bremelanotide [9].

Raynaud Phenomenon and PAH: Populations at Particular Risk

Women with PAH already have compromised cardiac reserve. Adding bremelanotide, with its transient vasodilatory and tachycardia-inducing effects, to a daily 40 mg tadalafil regimen could produce hemodynamic instability well beyond the average trial participant. The FDA label for Vyleesi explicitly warns against use in patients with serious cardiovascular conditions, and PAH falls squarely in that category [1][5].

The HealthRX clinical team developed the following pre-prescribing checklist for clinicians considering bremelanotide in a patient already on tadalafil:

1. Confirm the indication for tadalafil (PAH vs. Off-label vs. Erectile dysfunction in a partner who could share environmental hypotension risk).
2. Measure seated blood pressure at baseline and set a threshold: withhold bremelanotide if systolic is <100 mmHg.
3. Ask the patient to avoid alcohol and hot environments for at least 4 hours after bremelanotide injection, as both potentiate vasodilation.
4. Schedule a follow-up blood pressure check after the first combined-use event.
5. Document the risk-benefit discussion in the chart.

Monitoring Protocol Before and After Dosing

Clinical monitoring is the primary risk-mitigation tool because there is no dose adjustment for either drug that eliminates the interaction.

Pre-Dose Blood Pressure Check

The FDA label for bremelanotide requires a pre-dose blood pressure measurement before every administration [1]. This is not a formality. In the context of tadalafil co-use, clinicians should instruct patients to take their seated blood pressure using a validated home monitor and to withhold the bremelanotide injection if systolic is <100 mmHg or if they feel lightheaded, flushed, or unwell [1][10].

A validated automated upper-arm blood pressure monitor (validated per the British and Irish Hypertension Society protocol) reduces measurement error compared with wrist devices [10]. Patients should measure after 5 minutes of seated rest, consistent with American Heart Association measurement standards [11].

Post-Injection Monitoring Window

Peak hemodynamic effect of bremelanotide occurs at approximately 12 minutes post-injection [1]. Patients should remain seated or supine for at least 15 to 20 minutes after injection. If dizziness occurs, lying flat with legs elevated is the first-line response. Emergency services should be contacted if symptoms do not resolve within 15 minutes or if the patient loses consciousness.

Tadalafil's peak plasma concentration occurs 2 hours after an oral dose (daily dosing) or 30 minutes to 6 hours after as-needed dosing [5]. The overlap between bremelanotide's peak vascular effect (12 minutes) and tadalafil's sustained plasma levels (half-life 17.5 hours for daily dosing) means there is no timing window that completely eliminates hemodynamic overlap [5].

Nausea as a Confounding Factor

In the RECONNECT trials, nausea affected approximately 40% of bremelanotide users [4]. Nausea itself can trigger vasovagal responses, which further lower blood pressure. Patients already on tadalafil who experience bremelanotide-induced nausea face a compounded hemodynamic risk. The FDA label permits ondansetron pre-treatment for nausea prophylaxis, but the interaction between ondansetron and tadalafil (QT interval prolongation risk) adds another layer of clinical complexity [1][12].

A 2019 review in Drug Safety found that ondansetron at standard antiemetic doses (4-8 mg) produced a mean QTc prolongation of approximately 20 milliseconds in healthy adults [12]. Tadalafil itself has a low but non-zero QTc effect at supratherapeutic doses [5]. Stacking ondansetron on top of tadalafil and bremelanotide warrants an ECG baseline in patients with any preexisting QTc risk factors.

Dose Timing Considerations

No timing strategy eliminates the interaction, but some adjustments reduce peak overlap.

As-Needed Tadalafil

For patients using tadalafil 10 mg or 20 mg as needed, the drug reaches peak plasma concentration (Cmax) in 2 hours and has a half-life of 17.5 hours [5]. Administering bremelanotide at least 4 hours after a tadalafil dose puts the bremelanotide injection at a point where tadalafil plasma levels are declining but still approximately 80% of Cmax based on first-order kinetics. There is no timing window where tadalafil exposure is negligible given its long half-life.

Daily Tadalafil

Patients on tadalafil 2.5 mg or 5 mg once daily reach steady-state plasma concentrations within 5 days [5]. At steady state, tadalafil is continuously present. There is no safe "off" window. This population requires the most conservative approach: verify baseline BP before every single bremelanotide dose without exception.

Patient Counseling Points

Clear, specific instructions reduce the risk of adverse events.

Patients should be told to inject bremelanotide in the abdomen or thigh, not the arm, to reduce variability in absorption speed [1]. They should avoid alcohol entirely on the day of bremelanotide use, given alcohol's own vasodilatory and hypotensive effects, which compound tadalafil's PDE5-mediated vasodilation [5][13]. A 2017 study in Clinical Pharmacokinetics confirmed that moderate alcohol consumption (0.5 g/kg) potentiated tadalafil-related blood pressure reductions by a mean of 3.1 mmHg systolic compared with tadalafil alone [13].

Patients should also avoid prolonged sitting in hot water, saunas, or hot tubs for 3 to 4 hours after bremelanotide injection. Heat-induced peripheral vasodilation from these exposures further compounds the blood-pressure-lowering effects of both drugs [1].

Severity Classification and Clinical Takeaway

Drug interaction databases, including Lexicomp and Micromedex, classify the bremelanotide-tadalafil combination as a moderate interaction requiring clinical monitoring rather than an absolute contraindication [14]. The FDA label does not hard-contraindicate the pair, but its warnings about cardiovascular risk and pre-dose blood pressure requirements effectively make this a use-with-caution scenario [1].

The American Urological Association's 2018 guideline on erectile dysfunction, which governs much of PDE5 inhibitor prescribing, categorizes patients into cardiovascular risk tiers and notes that "patients in the intermediate or high cardiovascular risk category should not receive PDE5 inhibitors until their cardiac status has been fully evaluated" [15]. Women on tadalafil for PAH fall into the high-risk tier by definition, making bremelanotide co-use inadvisable in that population without cardiology input.

For low-risk patients, a typical example being a normotensive premenopausal woman taking low-dose tadalafil 5 mg daily for Raynaud phenomenon, the interaction is manageable with consistent pre-dose BP monitoring, alcohol avoidance, and a 15-minute post-injection rest period. Systolic blood pressure below 100 mmHg at any pre-dose check should trigger a dose hold and a call to the prescribing clinician.